Fuqua Professor David Ridley

Everything You Need to Know About FDA’s Priority Review Vouchers Worth $100’s of Millions.

Never Heard of These 'PRV's' but What a Potential Bonanza for the Recipients. They're transferable - as in they can be...

Adding Immix Biopharma (IMMX) to 2022 Biotech 12 Pack List.

Added to 12 Biotech Stocks we Expect to Double List. The Original Biotech 6-Pack from 2020, is Growing to...
Roland Rick Perry

Tax Loss Selling Bargain? Adding Aditxt (ADTX).

Adding Aditxt (ADTX) to the upcoming "2022 Biotech 6-Pack, Stocks We Expect to Double" Watch List.

Dalrada (DFCO). Our 11th and Latest Ten Bagger.

We've actually had many more than 11 ten-baggers, as we report on companies which aren't clients. This is our 11th client we...
VYRE Network

Report: VYRE Network (CAPV).

Update Report: Our First Internet Play in Ages, and It’s a Doozy. Reporting from the Great City...

The Race to Develop Therapeutics for COVID. The Small Caps Fight for a Treatment...

The Second Wave: Biopharma Players Race to Develop Therapeutics for COVID-19 (BioSPace) December 21. Revive Therapeutics (RVTTF), RedHill BioPharma...

Reuniting With the Affable Mr. Greg Halpern, 19 Years Later…

A Potential Christmas Present Arrives in our lap Early, From the Inventor of Crowdfunding and Winner of Incubator of The Year in...
CPRE Networks

Adding VYRE Network (CAPV) to the Watch List.

Look What We Found. Our First Internet Play in Ages, And It's a Doozy. We would categorize this...

He Shoots and He Scores. Dicerna (DRNA) up 78%.

Our Second $3.00 Watch List Company Gets Acquired for Over $1 Billion. As They say "You Can't Make This **** Up."

The Alkaline Water Company (WTER) Reports Record Second Quarter Revenue with 50% Year over...

$15.25 Million in Revenue is Best Quarter in Company History SCOTTSDALE, Ariz., November 09, 2021–(BUSINESS WIRE)–The Alkaline Water Company...

Latest article

Revive therapeutics

Our Best Risk to Reward Idea Ever?

Adding Revive Therapeutics (RVVTF, RVV.CN) to the "2022, Biotech 12 pack, 12 Biotech Stocks We Expect to...
Immunix Bio

ImmixBio (IMMX) Announces Positive Clinical Trial Safety Data.

Demonstrates 100% Completion of Planned Treatment Cycles. Immix Biopharma, Inc. Wed, January 19, 2022. ImmixBio...
Fuqua Professor David Ridley

Everything You Need to Know About FDA’s Priority Review Vouchers Worth $100’s of Millions.

Never Heard of These 'PRV's' but What a Potential Bonanza for the Recipients. They're transferable - as in they can be...